Lifecore Biomedical reported a significant net loss of $61.2 million for the nine months ended September 30, 2026, compared to a $20.9 million loss in the prior year, primarily driven by a $35.6 million non-cash change in the fair value of a related party debt derivative. Total revenues decreased to $82.7 million from $105.7 million year-over-year, and the company recently entered into a merger agreement with affiliates of Webster Equity Partners.
Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.
Term
Q3 2026
“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”
Paul Josephs, president and chief executive officer of Lifecore